Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats

Endocrinology

Volumn 147, Issue 5, 2006, Pages 2526-2534

  Buss, Sebastian J ^a   Backs, Johannes ^a,c   Kreusser, Michael M ^a   Hardt, Stefan E ^a   Maser Gluth, Christiane ^a   Katus, Hugo A ^a   Haass, Markus ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Theresienkrankenhaus ^*  (Germany)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; MAZINDOL; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NORADRENALIN; PRAZOSIN; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD PRESSURE; CONTROLLED STUDY; HEART MUSCLE; HEART PERFUSION; HEART VENTRICLE FUNCTION; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STATISTICAL SIGNIFICANCE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; BODY WEIGHT; ECHOCARDIOGRAPHY; ENDOTHELIN-1; HEART; HEART VENTRICLES; HEMODYNAMIC PROCESSES; MALE; MODELS, STATISTICAL; MYOCARDIUM; NEURONS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ORGAN SIZE; PERFUSION; RATS; RATS, INBRED DAHL; RATS, WISTAR; SALTS; SODIUM CHLORIDE; SPIRONOLACTONE;

EID: 33645848757     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-1167     Document Type: Article

References (46)

1. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD 1995 Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76:1259-1265
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
4. Weber KT, Villarreal D 1993 Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 71:3A-11A
5. Struthers AD, MacDonald TM 2004 Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61:663-670
6. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L 1990 Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730-1736
7. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F 1994 Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24:583-591
8. Weber KT 2001 Aldosterone in congestive heart failure. N Engl J Med 345:1689-1697
9. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, Yoshihara F, Kangawa K, Matsuoka H 2002 Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 39:1077-1082
10. Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M 2000 Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 47:274-283
11. Yamamoto K, Masuyama T, Sakata Y, Doi R, Ono K, Mano T, Kondo H, Kuzuya T, Miwa T, Hori M 2000 Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system. Cardiovasc Res 46:421-432
12. Takeda Y 2005 Role of cardiovascular aldosterone in hypertension. Curr Med Chem Cardiovasc Hematol Agents 3:261-266
13. Bayorh MA, Ganafa AA, Emmett N, Socci RR, Eatman D, Fridie IL 2005 Alterations in aldosterone and angiotensin II levels in salt-induced hypertension. Clin Exp Hypertens 27:355-367
14. Leimbach Jr WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL 1986 Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913-919
15. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T 1984 Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823
16. Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kubler W, Haass M 2001 The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 33:461-472
17. Bohm M, La Rosee K, Schwinger RH, Erdmann E 1995 Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25:146-153
18. Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62
19. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD 1996 Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667-1676
20. Liang CS, Fan TH, Sullebarger JT, Sakamoto S 1989 Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to β-adrenoceptor downregulation. J Clin Invest 84:1267-1275
21. Petch MC, Nayler WG 1979 Uptake of catecholamines by human cardiac muscle in vitro. Br Heart J 41:336-339
22. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, Tsuchihashi K, Shimamoto K 1998 Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 5:579-590
23. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 86:656-660
24. Backs J, Bresch E, Lutz M, Kristen AV, Haass M 2005 Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovasc Res 67:283-290
25. Park JB, Schiffrin EL 2001 ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37:1444-1449
26. Borst MM, Beuthien W, Schwencke C, LaRosee P, Marquetant R, Haass M, Kubler W, Strasser RH 1999 Desensitization of the pulmonary adenylyl cyclase system: a cause of airway hyperresponsiveness in congestive heart failure? J Am Coll Cardiol 34:848-856
27. Da Prada M, Zurcher 1976 Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19:1161-1174
28. Sander M, Bader M, Djavidani B, Maser-Gluth C, Vecsei P, Mullins J, Ganten D, Peters J 1992 The role of the adrenal gland in hypertensive transgenic rat TGR(mREN2)27. Endocrinology 131:807-814
29. Vecsei P, Abdelhamid S, Mittelstadt GV, Lichtwald K, Haack D, Lewicka S 1983 Aldosterone metabolites and possible aldosterone precursors in hypertension. J Steroid Biochem 19:345-351
30. Haass M, Cheng B, Richardt G, Lang RE, Schomig A 1989 Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 339:71-78
31. Kranzhofer R, Haass M, Kurz T, Richardt G, Schomig A 1991 Effect of digitalis glycosides on norepinephrine release in the heart. Dual mechanism of action. Circ Res 68:1628-1637
32. Langendorff O 1895 Untersuchungen am ueberlebenden Saeugetierherzen. Arch Ges Physiol 61:291-332
33. sα and a missense mutation in the α-myosin heavy chain. Circulation 105:614-620
34. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL 2002 Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510
35. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M 2003 Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41:574-581
36. Brilla CG, Matsubara LS, Weber KT 1993 Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-16A
37. Stier Jr CT, Chander PN, Rocha R 2002 Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10:97-107
38. 131I]iodobenzylguanidine. J Nucl Med 21:349-353
39. Quaschning T, Ruschitzka F, Shaw S, Luscher TF 2001 Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37:801-805
40. Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, Haass M 2003 Increased cardiac norepinephrine release in spontaneously hypertensive rats: role of presynaptic α-2A adrenoceptors. J Hypertens 21:1363-1369
41. Akers WS, Cassis LA 2004 Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload. Am J Physiol 286:H2151-H2158
42. Cittadini A, Monti MG, Isgaard J, Casaburi C, Stromer H, Di Gianni A, Serpico R, Saldamarco L, Vanasia M, Sacca L 2003 Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 58:555-564
43. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C 1999 Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99:2694-2701
44. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D 1992 Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471-477
45. Munch G, Rosport K, Bultmann A, Baumgartner C, Li Z, Laacke L, Ungerer M 2005 Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res 97:928-936
46. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF 2004 Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364:347-354